Quest Diagnostics (NYSE:DGX) had its price target raised by analysts at Mizuho from $210.00 to $235.00. They now have an "outperform" rating on the stock.
Quest Diagnostics (NYSE:DGX) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Quest Diagnostics (NYSE:DGX) was given a new $220.00 price target on by analysts at Evercore ISI.
Quest Diagnostics (NYSE:DGX) was given a new $220.00 price target on by analysts at Truist Financial Corporation.
Quest Diagnostics (NYSE:DGX) had its price target raised by analysts at Barclays PLC from $210.00 to $225.00. They now have an "overweight" rating on the stock.